It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We have previously identified a novel Aurora-A-mediated Serine 379 (S379) phosphorylation of a poly(C)-binding protein, hnRNPK, the overexpression of which is frequently observed in various cancers. It is known that the oncogenic Aurora-A kinase promotes the malignancy of cancer cells. This study aims to investigate the unexplored functions of hnRNPK S379 phosphorylation using MDA-MB-231 cells, a triple negative breast cancer cell that has amplification of the Aurora-A kinase gene. Accordingly, we established two cell lines in which the endogenous hnRNPK was replaced with either S379D or S379A hnRNPK respectively. Notably, we found that a phosphorylation-mimic S379D mutant of hnRNPK suppressed cell migration and, conversely, a phosphorylation-defective S379A mutant promoted migration. Moreover, Twist was downregulated upon hnRNPK S379 phosphorylation, whereas β-catenin and MMP12 were increased when there was loss of hnRNPK S379 phosphorylation in MDA-MB-231 cells. Furthermore, S379A hnRNPK increases stability of β-catenin in MDA-MB-231 cells. In conclusion, our results suggest that hnRNPK S379 phosphorylation regulates migration via the EMT signaling pathway.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 National Yang-Ming University, Department of Life Sciences and Institute of Genome Sciences, Taipei, Taiwan (GRID:grid.260770.4) (ISNI:0000 0001 0425 5914)
2 National Yang-Ming University, Institute of Traditional Medicine, Taipei, Taiwan (GRID:grid.260770.4) (ISNI:0000 0001 0425 5914)
3 Taipei Veterans General Hospital, Comprehensive Breast Health Center, Taipei, Taiwan (GRID:grid.278247.c) (ISNI:0000 0004 0604 5314)
4 National Yang-Ming University, Institute of Traditional Medicine, Taipei, Taiwan (GRID:grid.260770.4) (ISNI:0000 0001 0425 5914); Taipei Veterans General Hospital, Comprehensive Breast Health Center, Taipei, Taiwan (GRID:grid.278247.c) (ISNI:0000 0004 0604 5314)
5 National Yang-Ming University, Department of Life Sciences and Institute of Genome Sciences, Taipei, Taiwan (GRID:grid.260770.4) (ISNI:0000 0001 0425 5914); National Yang-Ming University, Institute of Biopharmaceutical Sciences, Taipei, Taiwan (GRID:grid.260770.4) (ISNI:0000 0001 0425 5914); National Yang-Ming University, Proteomics Research Center, Taipei, Taiwan (GRID:grid.260770.4) (ISNI:0000 0001 0425 5914); National Yang-Ming University, Aging and Health Research Center, Taipei, Taiwan (GRID:grid.260770.4) (ISNI:0000 0001 0425 5914)